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Abstract
Systemic lupus erythematosus (SLE) is characterized by production of a variety of autoanti-
bodies. Although anti-double-stranded DNA (anti-dsDNA) antibodies contribute to the path-
ogenesis of lupus nephritis (LN), they are not sufficient for diagnosis and evaluation of
disease activity. To obtain other autoantibodies associated with LN, we screened autoanti-
gens reacting with the sera of LN patients by using an N-terminal biotinylated protein library
created from a wheat cell-free protein production system. We screened 17 proteins that
showed higher positive signals in the active phase than in the inactive phase of SLE, and
higher positive signals in the serum of SLE patient with nephritis than in that of patient with-
out nephritis. Of these, two LN-associated autoantigens, ribosomal RNA-processing protein
8 (RRP8) and spermatid nuclear transition protein 1 (TNP1) were identified by immunopre-
cipitation and immunofluorescence of renal tissues. Circulating anti-RRP8 and anti-TNP1
autoantibodies were recognized and deposited as an immune complex (IC) in glomeruli. IC
was deposited preferentially in glomeruli rather than in other organs in C57BL/6 mice
injected with RRP8 or TNP1. ELISA analysis of sera from patients with various rheumatic
diseases demonstrated reactivity for RRP8 and TNP1 in 20% and 14.7% of SLE patients,
respectively, whereas there was little or no reactivity in patients with other rheumatic dis-
eases. Among SLE patients, 63.6% and 45.5% of those with LN were positive for anti-
RRP8 and anti-TNP1 antibodies, compared with 12.5% and 9.4% of SLE patients without
nephritis, respectively. Both proteins are cationic, and their respective antibodies did not
cross-react with dsDNA. These proteins released from apoptotic cells form ICs with each
autoantibody, and their ICs may become trapped at anionic sites in the glomerular base-
ment membrane, leading to deposition in glomeruli. These autoantibodies may be useful for
prediction of LN in subsets of SLE patients who are negative for anti-dsDNA antibodies.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by production of
a wide variety of autoantibodies directed at various self molecules present in the nucleus, cyto-
plasm and cell surface [1–3]. Lupus nephritis (LN) is one of the most serious manifestations of
SLE and is associated with significant morbidity and mortality [4, 5]. Renal biopsies demon-
strate the presence of immune complex (IC) deposits in the renal glomeruli of patients with
LN. The formation of glomerular immune deposits is a major event that initiates glomerular
injury and subsequent loss of renal function. However, the mechanisms leading to the forma-
tion of immune deposits and the development of renal lesions are not yet fully resolved. In
addition, the targets of pathogenic antibodies in glomeruli are also not well defined.
Anti-double-stranded DNA (anti-dsDNA) antibodies are involved in the pathogenesis of
LN, and their titer is correlated with disease activity [4–6]. However, the correlation between
anti-dsDNA antibodies and LN is clinically imprecise, as some patients with active nephritis
are negative for the antibodies, whereas some patients showing a persistently high antibody
titer may not have renal involvement [7]. In addition, deposition of anti-dsDNA antibodies in
glomeruli in LN accounts for no more than 10–20% of eluted IgG overall, indicating that many
antibodies other than anti-dsDNA antibodies may be associated with the pathogenesis of LN
[8]. To date, some autoantibodies such as anti-C1q, anti-nucleosome, anti-Sm, anti-α-actinin,
anti-α-enolase, anti-annexin II, anti-annexin AI, and anti-ribosomal P protein, have been
reported in patients with LN [9–28]. However, these autoantibodies are not sufficiently sensi-
tive or specific for prediction of LN or renal flares.
In the present study, to obtain clinical markers for the diagnosis and evaluation of disease
activity in LN patients, we screened autoantigens reactive with serum antibodies using an N-
terminal biotinylated protein library (BPL) produced using a wheat cell-free protein produc-
tion system, and a commercially available luminescence system (BPL-based screening method)
[29, 30]. The BPL-based screening method has a number of excellent characteristics, including
1) utilization of a high-throughput and genome-wide protein expression system, 2) specific
protein labeling for assay using unpurified protein samples, and 3) a high-throughput system
for detection of properly folded antigen. Therefore, this method is suitable for identification of
autoantigen proteins reacting with antibodies that recognize folded proteins, rather than dena-
tured or unfolded forms. In addition, since this system is fully automated, large numbers of
autoantigens can be screened easily and rapidly. From this system and subsequent immunopre-
cipitation analysis, we found two new candidates of LN-associated autoantigens, ribosomal
RNA-processing protein 8 (RRP8) [31] and spermatid nuclear transition protein 1 (TNP1)
[32]. Human RRP8 is a cationic protein consisting of 456 amino acids (a.a.), localized mainly
in the nucleolus. RRP8 is an essential component of the eNoSC (energy-dependent nucleolar
silencing) complex, which mediates silencing of ribosomal DNA (rDNA) in response to intra-
cellular energy status and acts by recruiting histone-modifying enzymes [33–35]. On the other
hand, human TNP1 is also a cationic protein consisting of 55 a.a. TNP1 is an abundantly
expressed basic protein in the sperm nucleus and participates in chromatin condensation by
replacing somatic-type histones with protamines during spermiogenesis [36]. Here we describe
the identification and characterization of RRP8 and TNP1 as LN-associated autoantigens.
Materials and Methods
Ethics statement
Approval for this study was obtained from the Institutional Review Board of Ehime University
Hospital. Paraffin-embedded, formalin-fixed renal sections obtained at autopsy from LN
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patients were also employed. Written informed consent was obtained from each patient, or
from the family in the case of autopsied patients. All in vivo mouse experiments were approved
by the Ehime University animal care committee.
Patients
Patients with the following diseases were analyzed in this study: SLE (n = 75), dermatomyosi-
tis/polymyositis (DM/PM) (n = 30), systemic sclerosis (SSc) (n = 16), mixed connective tissue
disease (MCTD) (n = 15), rheumatoid arthritis (RA) (n = 55), Sjögren syndrome (SS) (n = 12),
Behçet’s disease (BD) (n = 22), and ANCA-associated vasculitis (AAV) (n = 13). These diseases
were diagnosed according to the ACR (American College of Rheumatology), EULAR (The
European League Against Rheumatism), and international criteria [37–44]. In addition, 41
healthy individuals were also analyzed. Disease activity in patients with SLE was determined by
calculation of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), based on
clinical findings in the two weeks prior to sample collection [45]. The active and inactive phases
of LN were defined as 4 and 0 of the renal SLEDAI score, respectively. The diagnosis of LN
was verified by renal biopsy in 7 patients, and based solely on the SLEDAI definition in 4
patients who were not obtained informed consent of renal biopsy. Information on the charac-
teristics of 11 LN patients is shown in S1 Table.
Serum samples were frozen at -80°C until use. Formalin-fixed paraffin-embedded renal sec-
tions obtained from LN patients by kidney biopsy or autopsy were used in this study, as frozen
renal sections had not been stocked.
Preparation of a N-terminally biotinylated protein library using a wheat
germ cell-free protein synthesis system
A BPL was prepared using wheat germ extract (ENDEXT kits, CellFree Sciences, Matsuyama,
Japan) as described previously [29]. Briefly, we selected proteins encoded by genes in the
human autoimmune susceptibility loci associated with SLE, RA, etc. [46–48], as well as pro-
teins classified as “membrane proteins” and “proteins in the extracellular space” in the Gene
Ontology database, as tentative autoantigens. A total of 2,296 genes encoding these target pro-
teins were translated from a human full-length cDNA resource (mammalian gene collection,
MGC clone, DANAFORM, Tokyo, Japan). From the plasmid-inserted cDNA, transcription
templates were synthesized by split-primer polymerase chain reaction (PCR). The promoter
and transcription enhancer sequences for SP6 RNA polymerase, and the coding sequence of
the biotin ligase recognition peptide, were inserted into the contructs.
Cell-free construction of BPL was based on the previously described bilayer diffusion system
in which 1 μL (50 ng) of crude cell-free-expressed biotin ligase was added to the translation
layer and 500 nM D-biotin (Nacalai Tesque, Kyoto, Japan) was added to both the translation
and substrate layers [29]. In vitro transcription and cell-free protein synthesis for BPL were
performed with the GenDecoder 1000 robotic synthesizer (CellFree Sciences).
Antigen screening with the AlphaScreen assay
The AlphaScreen assay (PerkinElmer Life and Analytical Sciences, Boston, MA, USA) was car-
ried out using a 384-well Optiwell microtiter plate as described previously [30]. Briefly, 1 μL of
the translation solution containing biotinylated proteins was added to a well with 14 μL of
buffer containing 0.025 μL of serum. The mixture solution at a final concentration of 100 mM
Tris-HCl (pH 8.0), 0.01% (v/v) Tween 20 and 0.1% (w/v) bovine serum albumin (BSA), was
incubated at 26°C for 30 min. Then, 10 μL of a mixture of streptavidin-coated donor beads and
protein G-conjugated acceptor beads (PerkinElmer Life and Analytical Sciences) was added,
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and incubated at 26°C for 1 h in a dark box. The final concentration of the beads was 12 μg/mL
per well. Fluorescence emission at 520–620 nm was measured on the EnVision plate reader
(PerkinElmer Life and Analytical Sciences), and the resulting data were analyzed with the
AlphaScreen detection program. All repetitive mechanical procedures were performed on a
Biomek FX robotic workstation (Beckman Coulter, Fullerton, CA, USA). Translation solution
reacted without template RNA served as a negative control. Signals in the negative control well
were regarded as noise, and the signal/noise ratio was calculated.
Immunoprecipitation and immunoblotting
Immunoprecipitation analysis using biotinylated proteins was carried out as described previ-
ously with some modifications [29]. Briefly, 50 μL of translation mixture containing biotiny-
lated proteins was incubated with 150 μL of IP buffer [phosphate-buffered saline (PBS) with
0.1% (w/v) BSA and 0.15% (v/v) Tween 20] and 20 μL of serum overnight at 4°C. Immobilized
Protein G Sepharose (20 μL of 50% slurry, Protein G Sepharose 4 Fast Flow, GE Healthcare,
Buckinghamshire, UK) was added to each sample and incubated for 1 h at 4°C. After three
washes with IP buffer, samples were boiled for 5 min in sodium dodecyl sulfate (SDS) sample
buffer (Bio-Rad Lab, Hercules, CA, USA). Each sample was fractionated on SDS-12% poly-
acrylamide gels and transferred onto PVDF membranes (Merck Millipore, Billerica, MA,
USA). After blocking with 5% (w/v) skim milk in PBS overnight at 4°C, the membranes were
incubated with streptavidin-horseradish peroxidase (HRP) (Mabtech AB, Nacka Strand, Swe-
den) for 1 h at room temperature. After washing three times in PBS containing 0.1% (v/v)
Tween 20 (PBST), the biotinylated proteins on the membrane were detected by ECL detection
reagents (GE Healthcare) using an ImageQuant LAS4000 (GE Healthcare).
Purification of recombinant proteins in a cell-free system
RRP8 and TNP1 were prepared in a cell-free protein synthesis system using wheat germ ribo-
somal RNA [49]. A full-length cDNAs of RRP8 (human) and TNP1 (human and mouse) were
obtained from DANAFORM. A full-length cDNA of mouse RRP8 was prepared from spleens
of C56BL/6 mice with reverse transcriptase polymerase chain reaction (RT-PCR). The cDNA
of RRP8 or TNP1 was inserted into a pEUE01-His-TEV-N2 expression vector containing a His
tag region (CellFree Sciences). Both proteins were automatically synthesized by the Robotic
Protein Synthesizer Protemist DT II (CellFree Sciences). Briefly, 250 μL of transcription mix-
ture containing 25 μg of the plasmid DNA, 80 mMHEPES-KOH (pH 7.8), 16 mMmagnesium
acetate, 2 mM spermidine, 10 mM dithiothreitol, 2.5 mM each nucleoside triphosphate, 250 U
of SP6 RNA polymerase (Promega, Madison, WI, USA) and 250 U of RNasin (Promega) was
incubated for 6 h at 37°C. Then, the transcription solution containing transcribed mRNA was
mixed with 250 μL of wheat germ extract WEPRO7240H (CellFree Sciences) supplemented
with 1 μL of 20 mg/mL creatine kinase in a single well of a six-well plate. The substrate mix [30
mMHEPES-KOH (pH 7.8), 100 mM potassium acetate, 2.7 mMmagnesium acetate, 0.4 mM
spermidine, 2.5 mM dithiothreitol, 0.3 mM amino acid mix, 1.2 mM ATP, 0.25 mMGTP, and
16 mM creatine phosphate] in a volume of 5.5 mL was added on top of the translation mix and
then incubated at 17°C for 20 h. The reaction mixture was then applied on Ni Sepharose High
performance (GE Healthcare). His-tag-binding protein was eluted with elution buffer [50 mM
NaH2PO4, 300 mMNaCl, and 500 mM imidazole (pH 7.5)], dialyzed against PBS using a Mini
Dialysis kit (GE Healthcare), and the protein was stocked at -80°C until use.
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Enzyme-linked immunosorbent assay (ELISA)
Serum samples were assayed by ELISA using plates coated with purified RRP8 or TNP1 pro-
teins as described previously [50]. Briefly, flat-bottom 96-well plates (Thermo Scientific Japan,
Yokohama, Japan) were coated with the recombinant proteins purified by wheat germ cell-free
synthesis at 500 ng per well diluted in 0.05 M carbonate buffer (pH 9.6) at 4°C overnight. The
remaining free binding sites were blocked with blocking reagents (Blocking One; Nacalai Tes-
que) for 1 h at room temperature. Wells were incubated with serum samples diluted 1:500 for 2
h and subsequently with HRP-conjugated goat anti-human IgG (Fab)2 (Abcam, Cambridge,
UK) for 1 h. The antibody binding was visualized by incubation with tetramethylbenzidine
(SurModics, Eden Prairie, MN, USA). The reaction was stopped with stop solution (SurMo-
dics). The optical density at 450 nm (OD450) was then read with a FlexStation 3 (Molecular
Devices Japan, Tokyo, Japan). All incubations were followed by three washes with PBST. Sam-
ples were tested in duplicate, and the antibody units were calculated from the OD450 results
using a standard curve obtained from serial concentrations of serum from each LN patient con-
taining a high titer of each antibody.
The anti-dsDNA antibodies in sera from humans and mice were analyzed using commercial
ELISA kits (MBL, Nagoya, Japan) in accordance with the manufacturer’s protocol. Anti-RRP8
and anti-TNP1 antibodies in sera from mice were measured as described above, using HRP-
conjugated goat anti-mouse IgG (Fab)2 (GeneTex, Irvine, CA, USA). We estimated the glomer-
ular filtration rate (GFR) using the following equation: eGFR (mL/min/1.73 m2) = 194 x serum
creatinine (-1.094) x age (-0.287) x 0.739 (if female) [51].
Induction of glomerulonephritis in mice
Female 8-week-old C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan), and housed
under specific pathogen-free conditions. The mice were immunized subcutaneously with 20 μg of
purified protein (RRP8 or TNP1) in 100 μL Freund’s complete adjuvant on day 0 and in Freund’s
incomplete adjuvant on day 14, and then boostered intravenously from the tail vein every 10
days. Proteinuria was measured semiquantitatively using urine dipsticks (Siemens Healthcare
Diagnostics Japan, Tokyo, Japan). After detection of proteinuria (7–9 injections), the mice were
sacrified and their sera and the organs such as kidneys, lungs, spleens and livers were stocked.
Immunofluorescence staining
The rabbit anti-human RRP8 (Atlas Antibodies, Stokholm, Sweden) and rabbit anti-human
TNP1 (Atlas Antibodies) antibodies were labeled with a Zenon Alexa Fluor 546 rabbit IgG
Labeling Kit (Life Technologies Japan, Tokyo, Japan) in accordance with the manufacturer’s
instructions. Formalin-fixed, paraffin-embedded kidney sections of biopsy or autopsy speci-
mens from LN patients were processed for double immunofluorescence labeling. Briefly,
deparaffinized sections were incubated with 10% normal donkey serum for 15 min at room
temperature, followed by incubation with rabbit anti-human IgG (DAKO Japan, Kyoto, Japan)
or rabbit anti-human C3 antibody (DAKO Japan) for 1 h at room temperature. After washing
with Tris-buffer saline and 0.05% (v/v) Tween 20, the specimens were incubated with FITC-
conjugated donkey anti-rabbit IgG antibody for 1 h at room temparature. Subsequently, the
specimens were incubated with Zenon Alexa Fluor 546-labeled anti-RRP8 or anti-TNP1 anti-
body at 4°C overnight, then observed and photographed with a BZ-9000 fluorescence micro-
scope (Keyence Japan, Osaka, Japan).
Cryostat tissue sections from mice were also analyzed by double immunofluorescence using
a combination of anti-human RRP8 or anti-human TNP1 antibody and anti-mouse IgG anti-
body. The rabbit anti-human RRP8 and rabbit anti-human TNP1 antibodies were labeled with
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Zenon Alexa Fluor 568 rabbit IgG Labeling kit (Life technologies Japan), and the rabbit anti-
mouse IgG antibody (Bethyl Laboratories, Montgomery, TX, USA) was labeled with Zenon
Alexa Fluor 488 rabbit IgG Labeling kit. The sections were blocked with 2% (w/v) BSA in PBS
for 1 h at room temperature and then permeabilized for 1 h at room temperature using 4% (w/
v) BSA and 0.2% (v/v) Triton X-100 in PBS. Subsequently, the sections were incubated with
Zenon Alexa Fluor 568-labeled anti-human RRP8 or anti-human TNP1 antibody and Zenon
Alexa Fluor 488-labeled anti-mouse IgG antibody for 2 h at room temperature.
The phenotypes of the infiltrating cells in renal tissues were also analyzed by immunofluo-
rescence staining using cryostat kidney sections and the following Alexa Fluor 488-labeled anti-
bodies (BioLegend Japan KK, Tokyo, Japan): hamster anti-mouse CD3εmonoclonal antibody
(MoAb) (145-2C11); rat anti-mouse CD4 MoAb (GK1.5); rat anti-mouse CD8a MoAb (53–
6.7); rat anti-mouse CD11b MoAb (M1/70); and rat anti-mouse Ly-6G/Ly-6C (Gr-1) MoAb
(RB6-8C5). Quantitative analysis of infiltrating cells in glomerular and tubulointerstitial areas
was performed as follows: glomerular areas, cell counts in 20 random glomeruli; and tubuloin-
terstitial areas, 10 random fields at x400 magnification.
Real-time PCR for cytokines in the mouse kidney
The expressions of cytokines were quantified by real-time PCR (qRT-PCR). Briefly, for
qRT-PCR analysis, total RNAs were extracted from snap-frozen kidneys of all mice in each
group using Sepasol-RNA I Super G reagent (Nacalai Tesque). The cDNA was prepared with a
SuperScript III CellsDirect cDNA synthesis system (Invitrogen, Carlsbad, CA, USA). The
expressions of the cytokine genes were quantified using a QuantiTect SYBR Green PCR kit
(Qiagen, Valencia, CA, USA) in a 7500 Real Time PCR System (Applied Biosystems, Tokyo,
Japan), and corrected with a hypoxanthine phosphoribosyl transferase 1 (HPRT1) control.
Amplifications were done in a total volume of 25 μL for 45 cycles of 15 s at 95°C and 1 min at
60°C. Samples were run in triplicate and their relative expression was determined by normaliz-
ing the expression of each target to HPRT1 and then comparing this normalized value with the
normalized expression in a reference control sample to calculate the fold change value. The
primers for the amplicons spanned intron/exon boundaries to minimize any amplification of
genomic DNA. The primer sequences were as follows: IL-4, forward 5’-ACGGAGATGGAT
GTGCCAAAC-3’ and reverse 5’-AGCACCTTGGAAGCCCTACAGA-3’; IL-6, forward 5’-
CAACGATGATGCACTTGCAGA-3’ and reverse 5’-CTCCAGGTAGCTATGGTACTCCAGA-
3’; IL-17A [52], forward 5’- GACCAGGATCTCTTGCTGGA-3’ and reverse 5’- GGACTCT
CCACCGCAATGA-3’; IFN-γ, forward 5’-CGGCACAGTCATTGAAAGCCTA-3’ and reverse
5’-GTTGCTGATGGCCTGATTGTC-3’; TNF-α, forward 5’-AGCGAGGACAGCAAGG
GACTA-3’ and reverse 5’-GAGCTATTTCCAAGATGTTCTGGAG-3’; and HPRT1, forward
5’-TTGTTGTTGGATATGCCCTTGACTA-3’ and reverse 5’-AGGCAGATGGCCACAG
GACTA-3’.
Immunoelectronmicroscopy
The mouse kidneys were fixed for 30 min at 4°C in 4% paraformaldehyde and 0.1% glutaralde-
hyde in phosphate buffer (0.1 M sodium/potassium phosphate buffer, pH 7.3), dehydrated,
and embedded in LRWhite resin (Polysciences, Warrington, PA. USA). Ultrathin sections
(<60~80 nm), cut with a Leica Ultracut S (Leica, Wetzlar, Germany), were mounted on nickel
grids. Nonspecific labeling was blocked by preincubation with 5% normal goat serum, 5% BSA,
and 0.1% Tween 20 in PBS for 3 h at room temperature. For double immunogold labeling, the
sections were first incubated with rabbit anti-human RRP8 or rabbit anti-human TNP1 anti-
body (Atlas Antibodies) at 4°C overnight and washed three times in PBT (0.005% Tween 20 in
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PBS). Then the sections were incubated with 10-nm-gold-conjugated anti-rabbit IgG antibody
and 5-nm-gold-conjugated anti-mouse IgG antibody (British BioCell Int., Dundee, UK),
washed again twice in PBT, then twice in distilled water, and air-dried. Finally, the sections
were contrasted with a saturated solution of uranyl acetate in water (20 min) and observed in a
JEM1230 electron microscope (JEOL, Tokyo, Japan) equipped with a CCD camera (Model
SC1000; Gatan, Pleasanton, CA, USA).
PCR detection of RRP8 and TNP1 in the human tissues
To examine the expressions of RRP8 and TNP1 in various human tissues, we performed PCR
using MTC (multiple tissue cDNA) cDNA panels (Clontech, Mountain View, CA, USA) in
accordance with the manufacturer’s instructions. The primer sequences were as follows: RRP8,
forward 5’- GACCCTCATGTTCGAAGAGC-3’ and reverse 5’-AACCAGGTCTTGGCTCA
CAG-3’; TNP1, forward 5’-TGGCAGAACTTACCATGTCG-3’ and reverse 5’-GGGGAA
AAACAGCCAACATA-3’; and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), forward
5’-TGAAGGTCGGAGTCAACGGATTTGGT-3’ and reverse 5’-CATGTGGGCCATGAGGTC
CACCAC-3’. The required fragments were amplified using TaKaRa Ex Taq (Takara Bio, Shiga,
Japan). cDNA was subjected to 35 cycles of PCR (94°C for 30 s, and 68°C for 2 min) to detect
TNP1 and G3PDH, and to 35 cycles (94°C for 30 s, and 68°C for 4 min) to detect RRP8.
Statistical analysis
Comparisons between groups were examined using the Mann-Whitney U test. Correlations
were expressed as Spearman rank correlation coefficients. Differences at probability (p) values
of<0.05 were considered significant.
Results
Screening of autoantigens associated with LN using a biotinylated
human autoantigen library
To screen LN-associated autoantigens, we selected serum samples from two SLE patients:
patient A with nephritis but without serositis, and patient B with serositis but without nephritis
(S2 Table). Using the AlphaScreen assay, a total of 2,296 biotinylated proteins were evaluated
for their reactivity with antibodies in the serum from both patients in the active and inactive
disease phases. Consequently, in comparison with sera taken in the inactive phase, 456 and 525
proteins showed higher positive signals in the active phase in patients A and B, respectively.
Among these proteins, we selected 17 that showed a high luminescence signal (more than 3) in
patient A and higher positive signals in the serum from patient A than in the serum from
patient B (Table 1).
Identification of LN-associated autoantigens by immunoprecipitation
The biotinylated proteins of 17 autoantigens were prepared using the wheat germ cell-free pro-
tein synthesis system. Immunoprecipitation analysis using these biotinylated proteins was per-
formed using sera from patients with the following diseases: 5 with active LN, 5 with SLE
without nephritis, 5 with DM/PM, and 5 with SSc (S3 Table). Antibodies against RRP8, TNP1,
sperm protamine P1 (PRM1), and protamine 2 (PRM2), were detected in the sera from SLE
patients, while antibody against junctional sarcoplasmic reticulum protein 1 (JSRP1) was
detected not only in the sera from SLE patients but also in sera from DM and SSc patients. The
antibodies against PRM1 and PRM2 were detected in the sera from SLE patients with and with-
out nephritis, although these positive signals were weak. Antibodies against RRP8 and TNP1
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were detected specifically in patients with LN. As shown in Fig 1A and 1B, two proteins, RRP8
and TNP1, reacted with the sera from 2 and 1 LN patients, respectively. These two proteins did
not react with any serum from healthy controls, SLE patients without nephritis, or DM/PM
and SSc patients used in this experiment. These findings suggest that RRP8 and TNP1 are asso-
ciated with LN.
Table 1. Screening of 17 autoantigens associated with LN using a biotinylated human autoantigen library.
Gene Protein name Luminescence
signal
Molecular mass
(kDa)
Expected isoelectric
point
patient
A
patient
B
RRP8 Ribosomal RNA-processing protein 8 37.94 7.88 50.7 9.87
GABARAPL2 Gamma-aminobutyric acid receptor-associated protein-like
2
25.93 2.23 13.7 8.22
PRM2 Protamine-2 17.44 1.27 13.1 12.08
TNP1 Spermatid nuclear transition protein 1 15.17 1.17 6.4 12.33
USP10 Ubiquitin carboxyl-terminal hydrolase 10 11.97 8.10 87.1 5.06
FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4 10.71 2.71 51.8 5.22
CLIC5 Chloride intracellular channel protein 5 8.47 1.78 46.5 4.55
UBL5 Ubiquitin-like protein 5 8.15 1.16 8.5 8.50
TAF11 Transcription initiation factor TFIID subunit 11 7.78 5.22 23.3 4.61
JSRP1 Junctional sarcoplasmic reticulum protein 1 7.78 5.04 36.3 9.89
SAMHD1 Deoxynucleoside triphosphate triphosphohydrolase
SAMHD1
7.02 3.44 72.2 6.86
ADAP2 Arf-GAP with dual PH domain-containing protein 2 5.15 1.42 44.3 9.71
TRIP10 Cdc42-interacting protein 4 5.05 1.37 68.4 5.49
ETS2 Protein C-ets-2 4.86 1.59 53.0 4.76
PEX26 Peroxisome assembly protein 26 4.53 1.68 33.9 6.09
NHP2L1 NHP2-like protein 1 4.19 2.58 14.2 8.41
PRM1 Sperm protamine P1 3.64 1.11 6.8 12.25
Luminescence signal was calculated as the signals/noise ratio. Expected isoelectric point was estimated using an online calculator (http://isoelectric.ovh.
org/).
doi:10.1371/journal.pone.0126564.t001
Fig 1. Immunoprecipitation of RRP8 and TNP1 with sera from patients with rheumatic diseases.Reprisentative photographs are shown. (A) RRP8
(50.7 kDa) (B) TNP1 (GST-tagged, 32.4 kDa). LN; active lupus nephritis, SLE; systemic lupus erythematosus without active lupus nephritis, DM;
dermatomyositis, SSc; systemic sclerosis, cont; healthy control.
doi:10.1371/journal.pone.0126564.g001
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Deposition of anti-RRP8 and anti-TNP1 antibodies in glomeruli of LN
patients
To reveal whether anti-RRP8 and anti-TNP1 antibodies are deposited in glomeruli of LN
patients, double immunofluorescence was performed using a combination of anti-RRP8 or
anti-TNP1 antibodies and anti-IgG or anti-C3 antibodies. Kidney sections obtained by renal
biopsy and autopsy from LN patients were analyzed in this study. Paraffin sections, and not
frozen sections, were used as no frozen sections had been stocked. Therefore, nonspecific fluo-
rescence due to red blood cells was evident (S1 Fig). As shown in Fig 2, in LN1 and Autopsy1,
coexistence of RRP8 and IgG or C3 was detected in the sub-epithelial area of the glomeruli,
showing a dotted pattern, and in the mesangial and sub-epithelial areas, respectively. On the
other hand, in LN2 and Autopsy2, coexistence of TNP1 and IgG or C3 was revealed along the
basement membrane, exhibiting a linear pattern. Anti-RRP8 antibody was deposited in glo-
meruli of 3 LN patients, while anti-TNP1 antibody was deposited in glomeruli of 3 LN patients
(Table 2). These findings confirmed that anti-RRP8 and anti-TNP1 autoantibodies were
deposited as IC in the glomeruli of some LN patients.
Serum levels of anti-RRP8 and anti-TNP1 antibodies in patients with
rheumatic diseases
We compared the circulating levels of anti-RRP8 and anti-TNP1 antibodies among patients
with rheumatic diseases using ELISA. We analyzed a total of 238 serum samples obtained from
patients with various rheumatic diseases (S4 Table). When the cut-off value was considered to
be the mean plus 5 standard deviations (SD) for 41 healthy control sera, the cut-off level for
anti-RRP8 and anti-TNP1 antibodies was set at 9.1 units and 10.6 units, respectively. Among
these serum samples, anti-RRP8 antibody was positive in 20 patients; 15 SLE, 1 DM/PM, 3 RA
and 1 BD (Fig 3A). Among the SLE patients, the positive rate of anti-RRP8 antibody was signif-
icantly higher in LN than that in SLE without nephritis (63.6% (n = 7) vs 12.5% (n = 8), respec-
tively; p = 0.00017, odds ratio 12.25, 95% confidence interval 2.9–51.4). On the other hand, 14
were positive for anti-TNP1 antibody; 11 SLE, 1 RA and 2 BD (Fig 3B). The frequency of anti-
TNP1 antibody was significantly higher in the SLE patients with nephritis than in those with-
out nephritis (45.5% (n = 5) vs 9.4% (n = 6), respectively; p = 0.002, odds ratio 8.06, 95% confi-
dence interval 1.8–34.5). These findings indicate that both anti-RRP8 and anti-TNP1
antibodies are strongly associated with LN.
In the SLE cohort, the levels of anti-dsDNA antibodies as well as the SLEDAI scores were
weakly correlated with the levels of anti-RRP8 and anti-TNP1 antibodies (Fig 4, Table 3). Com-
plement factor 3 (C3) was correlated with anti-TNP1 antibody, and complement factor 4 (C4)
was correlated with both anti-RRP8 and anti-TNP1 antibodies. No correlation with eGFR was
evident (Table 3).
Among 11 patients with active LN, 7 were compared for their levels of anti-RRP8 and anti-
TNP1 antibodies between the active (at onset) and inactive (after remission) phases. In the
other 4 patients, the sera after remission had not been stocked. Both the anti-RRP8 and anti-
TNP1 antibodies were significantly decreased in the inactive phase (Fig 5). The SLEDAI scores
and the levels of anti-dsDNA antibodies were also decreased, and the levels of C3 and C4 were
increased significantly, although some patients still retained high titers of anti-dsDNA antibod-
ies or hypocomplementemia even after improvement of nephritis. In LN1, the level of anti-
RRP8 antibody decreased from 11.7 units to 1.2 units after remission, whereas that of anti-
dsDNA antibodies increased from 65.7 IU/ml to 77.8 IU/ml. In LN2, the level of anti-TNP1
antibody decreased from 11.9 units to 3.7 units after remission, whereas the level of anti-
dsDNA antibodies increased from 24.9 IU/ml to 49.1 IU/ml. These findings suggest that the
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Fig 2. Double immunofluorescence of RRP8 or TNP1 and IgG or C3 in renal sections from patients with LN. Formalin-fixed, paraffin-embedded
sections of biopsy or autopsy specimens from LN patients were processed for double immunofluorescence staining. Representative photographs are shown.
The specimens were stained with Alexa 546-conjugated anti-RRP8 or anti-TNP1 antibodies (red) and with FITC-conjugated anti-IgG or anti-C3 antibodies
(green). (A) The same glomeruli were stained with periodic acid-Schiff. (B) Co-presence of RRP8 and C3 was detected along the sub-epithelial area of the
glomeruli showing a dotted pattern (arrowhead) in LN1. Also in Autopsy1, both RRP8 and IgG signals were detected in the mesangial area as well as in the
sub-epithelial area (arrowhead). (C) Co-presence of TNP1 and IgG was revealed along the basement membrane showing a linear pattern in LN2, as was the
case for TNP1 and C3 in Autopsy2. The bold and strong autofluorescence in each of the panels is mainly due to red blood cells.
doi:10.1371/journal.pone.0126564.g002
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levels of anti-RRP8 and anti-TNP1 antibodies do not correlate with those of anti-dsDNA anti-
bodies in some LN patients.
Induction of IC-deposited glomerulonephritis in mice by immunization
with RRP8 or TNP1 antigen
In our first experiment, we examined whether anti-RRP8 and anti-TNP1 antibodies were pres-
ent in the sera of MRL/lpr mice. MRL/lpr mice spontaneously develop glomerular disease,
which becomes noticeable by the age of 12 weeks, in association with an increase of circulating
ICs, autoantibody production and cytokine abnormalities, closely resembling those seen in
human LN [53]. Consequently, anti-RRP8 and anti-TNP1 antibodies were not detectable in
the sera of 8-week-old MRL/lpr mice. MRL/lpr mice showed a significant increase in both anti-
RRP8 and anti-TNP1 autoantibodies at the ages of 12 weeks and 20 weeks (S2 Fig). However,
we were unable to examine immune deposits of RRP8 and TNP1 in the kidneys of MRL/lpr
mice, since no antibodies against mouse RRP8 or mouse TNP1 suitable for histological analysis
were available commercially.
Next, we examined whether IC would be formed by injection of human RRP8 or TNP1 into
C57BL/6 mice and whether glomerulonephritis would occur predominantly when IC was
formed with RRP8 or TNP1. C57BL/6 mice were injected repeatedly with recombinant human
RRP8 or TNP1 protein. C57BL/6 mice are not prone to autoimmune disease, but after 7–9
injections with RRP8 or TNP1, they demonstrated proteinuria (Fig 6A). In the sera of these
injected mice, a high titer of anti-RRP8 or anti-TNP1 antibody was evident, but anti-dsDNA
antibodies were negative (Fig 6B–6D). This indicates that RRP8 and TNP1 do not cross-react
with anti-dsDNA antibodies. In kidneys, some glomeruli of RRP8-injected mice showed a
slight enlargement of glomeruli with thickening of capillary wall and endocapillary prolifera-
tion with infiltrating leukocytes as same as those of TNP1-injected mice (Fig 7A). IC deposits
in cryostat kidney sections were analyzed by double immunofluorescence using a combination
of anti-RRP8 or anti-TNP1 antibody and anti-IgG antibody. As shown in Fig 7B, in RRP8-in-
jected mice, co-presence of RRP8 and IgG was evident in sub-endothelial and sub-epithelial
regions with a coarse granular pattern. In TNP1-injected mice, co-presence of TNP1 and IgG
was also demonstrated as a granular pattern in the sub-endothelial regions of glomeruli.
Moreover, to determine the deposition of ICs involving RRP8 or TNP1, immunoelectron
microscopy was performed. Both RRP8-injected and TNP1-injected mice revealed
Table 2. Deposition of RRP8 and/or TNP1 in renal sections obtained by biopsy and autopsy from LN
patients.
Case No. RRP8 TNP1
LN1 Class III(A)+V ++
LN2 Class III(A) + ++
LN3 Class IV-G(A)+V +
LN4 Class II
LN5 Class III(A)+V
LN6 Class III(A/C)
LN7* Class V not examined
Autopsy1 Class II +
Autopsy2 Class III(A/C)+V +
Autopsy3 Class III(C)
*Double immunoﬂuorescence in kidney section of LN7 was not performed because of poor sample.
doi:10.1371/journal.pone.0126564.t002
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subendothelial electron-dense deposits in low-power view (Fig 8A and 8C), especially around
the border of pericapillary and perimesangial areas. High magnification demonstrated adjacent
RRP8 or TNP1 represented by deposition of 10-nm gold particles and IgG represented by
5-nm gold particles (Fig 8B and 8D). These findings also indicate the deposition of IC involving
RRP8 or TNP1 in glomeruli. On the other hand, inflammatory changes such as vasculitis and
Fig 3. Serum levels of anti-RRP8 (A) and anti-TNP1 (B) antibodies in patients with rheumatic diseases.Cut-off values for positivity (9.1 units for anti-
RRP8 antibody and 10.6 units for anti-TNP1 antibody) are indicated by the dotted lines. LN, lupus nephrits; SLE, systemic lupus erythematosus without LN;
DM, dermatomyositis; PM, polymyositis; SSc, systemic sclerosis; MCTD, mixed connective tissue disease; RA, rheumatoid arthritis; SS, Sjögren syndrome;
BD, Behçet’s disease; AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis.
doi:10.1371/journal.pone.0126564.g003
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infiltrating inflammatory cells were hardly observed in the lung, liver and spleen of both
RRP8-injected and TNP1-injected mice (S3–S9 Figs). In addition, IC deposits with RRP8 or
TNP1 were not detected in the lung, liver and spleen of both RRP8-injected and TNP1-injected
mice by immunofluorescence staining (S3–S9 Figs). These findings indicate that the IC formed
with RRP8 or TNP1 is deposited preferentially in glomeruli, rather than in other organs.
Fig 4. Relationship between anti-RRP8 or anti-TNP1 antibody and clinical findings in SLE patients. (A) anti-RRP8 antibody and anti-dsDNA
antibodies, (B) Anti-RRP8 antibody and SLEDAI, (C) anti-TNP1 antibody and anti-dsDNA antibodies, (D) anti-TNP1 antibody and SLEDAI. SLEDAI,
systemic lupus erythematosus disease activity index. Correlations were expressed as Spearman rank correlation coefficients. P values of <0.05 were
considered significant.
doi:10.1371/journal.pone.0126564.g004
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Analysis of infiltrating cells and cytokine expression in the kidneys of
RRP8-injected and TNP1-injected mice
Next, we analyzed the infiltrating cells in glomerular and tubulointerstitial areas in control,
RRP8-injected and TNP1-injected mice. As shown in Fig 9A, there was no significant differ-
ence in the composition of infiltrating cells in glomerular and tubulointerstitial areas between
Table 3. Correlation between anti-RRP8 or anti-TNP1 antibody level and clinical findings in SLE patients.
Anti-RRP8 antibody Anti-TNP1 antibody
Spearman’s rs p value Spearman’s rs p value
SLEDAI 0.286 0.0096 0.292 0.0082
anti-dsDNA antibody (IU/ml) 0.327 0.0031 0.286 0.0096
C3 (mg/dL) -0.187 0.0902 -0.228 0.0388
C4 (mg/dL) -0.363 0.0010 -0.331 0.0027
eGFR (mL/min/1.73 m2) 0.208 0.0602 0.090 0.4131
Correlations were expressed as Spearman rank correlation coefﬁcients. P values of <0.05 were considered signiﬁcant.
doi:10.1371/journal.pone.0126564.t003
Fig 5. Changes in antibody levels and clinical findings in patients with lupus nephritis.▲ LN1, ♦ LN2, ● LN3, ^ LN4,  LN5, □ LN6, ■ LN7. (A) Anti-
RRP8 antibody, (B) anti-TNP1 antibody, (C) SLEDAI, (D) anti-dsDNA antibody, (E)C3, and (F) C4. The active and inactive phases of LN were defined as 4
and 0 of the renal SLEDAI score, respectively.
doi:10.1371/journal.pone.0126564.g005
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Fig 6. Measurement of proteinuria (A) and anti-RRP8 (B), anti-TNP1 (C) or anti-dsDNA (D) antibodies
in murine serum samples. Proteinuria was assessed before sacrifice. The urine diluted 1:10 was examined
and graded with a score of 0 (<30mg/dL); 1 (30-99mg/dL); 2 (100-299mg/dL); or 3 (300-999mg/dL). Serum
samples were assayed by ELISA using purified human RRP8 or TNP1 protein. RRP8- or TNP1-mice; C57BL/
6 mice injected repeatedly with RRP8 or TNP1, respectively. normal; normal C57BL/6 mice.
doi:10.1371/journal.pone.0126564.g006
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RRP8-injected and TNP1-injected mice. The majority of the infiltrating cells were CD11b-pos-
itive (macrophages) and CD3-positive (pan-T cells) in the kidneys of RRP8-injected and
TNP1-injected mice. In the glomerulus, the numbers of infiltrating macrophages and T cells in
RRP8-injected and TNP1-injected mice were 5-fold and 2-fold higher than those in control
mice, respectively. In the tubulointerstitium, the numbers of infiltrating macrophages and T
cells in RRP8-injected and TNP1-injected mice were 2-fold and 4-fold higher than those in
control mice, respectively. These findings indicate that macrophages in the glomerulus and T
cells in the tubulointerstitium predominantly infiltrate the kidneys of RRP8-injected and
TNP1-injected mice. Among CD3-positive cells in the glomerulus and tubulointerstitium, the
proportions of CD4- and CD8-positive cells were similar.
Fig 7. Double immunofluorescence of RRP8 or TNP1 and IgG in renal sections from RRP8-injected or TNP1-injected mice.Cryostat kidney sections
frommice were analyzed by double immunofluorescence staining with a combination of anti-human RRP8 or anti-human TNP1 antibody and anti-mouse IgG
antibody. The specimens were stained with Alexa 568-conjugated anti-RRP8 or anti-TNP1 antibodies (red) and with Alexa 488-conjugated anti-murine IgG
antibody (green). (A) Photomicrograph of representative glomeruli of RRP8- and TNP1-injected mice (periodic acid-Schiff staining). Both manifested the
slight enlargement of glomeruli with thickening of capillary wall (arrows) as well as the endocapillary proliferation with leukocytes (arrow head). (B) RRP8
signals coexisted with IgG signals in the sub-endothelial (arrows) and sub-epithelial (arrowhead) regions, exhibiting a granular pattern. On the other hand,
TNP1 signals coexisted with IgG signals in the sub-epithelial region (arrows).
doi:10.1371/journal.pone.0126564.g007
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Using qRT-PCR, we compared the expression levels of cytokines in the kidneys among con-
trol, RRP8-injected and TNP1-injected mice. As shown in Fig 9B, the expression levels of IL-6
and IFN-γ in both RRP8-injected and TNP1-injected mice were increased significantly relative
to those in control mice. Expression of IL-17A was undetectable with qRT-PCR using other
two primer sets (data not shown). Furthermore, in RRP8-injected and TNP1-injected mice, the
expression level of IFN-γ was high relative to those of IL-4 and IL-17A. This demonstrates that
a Th1 immune response, rather than a Th2 or Th17 immune response, occurs predominantly
in the kidneys of RRP8-injected and TNP1-injected mice.
Discussion
In the present study, we identified two novel autoantigens—RRP8 and TNP1—associated with
LN using an N-terminal biotinylated protein library created from a wheat cell-free protein pro-
duction system. Our main findings were as follows: Circulating anti-RRP8 and anti-TNP1
autoantibodies were detected and deposited as ICs in the glomeruli of some LN patients; the
Fig 8. Immunoelectron microscopy of kidney sections from RRP8-injected (A and B) or TNP1-injected (C and D) mice. Photographs show the
characteristic dense deposit in the subendothelial part especially at around the border of pericapillary and perimesangial areas. Panel B (anti-RRP8) and
Panel D (anti-TNP1) show the high-power view of the deposition which manifests the adjacent (within 30nm) of RRP8 or TNP1 represented by 10-nm-gold
particles and IgG represented by 5-nm-gold particles (circle area). *, electron-dense deposit; PD, podocyte; GBM, glomerular basement membrane.
doi:10.1371/journal.pone.0126564.g008
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positivity rates and levels of anti-RRP8 and anti-TNP1 autoantibodies were significantly higher
in SLE patients with nephritis than in those without nephritis, and both antibodies were scarce
or lacking in sera from patients with various other rheumatic diseases; ICs formed with human
RRP8 or TNP1 after injection into C57BL/6 mice were deposited preferentially in glomeruli
rather than in other organs; a Th1 immune response occurred predominantly in the kidneys of
RRP8-injected and TNP1-injected mice; and these ICs may be trapped via anionic sites in the
GBM, leading to deposition in glomeruli, since both antigens are cationic and their antibodies
did not cross-react with dsDNA.
Fig 9. Analysis of infiltrating cells (A) and cytokine expression (B) in the kidneys of RRP8-injected and TNP1-injected mice. (A)Quantitative analysis
of mononuclear cells in glomerular and tubulointerstitial areas was performed in control, RRP8-injected and TNP1-injected mice. Values are the mean and
SD of infiltrating and parenchymal cells (glomerular, cell counts in 20 random glomeruli; and tubulointerstitial, 10 random fields at x400 magnification). (B)
qRT-PCR analysis was performed on total RNA prepared from kidneys of all mice of each group. Results are calculated as a ratio of cytokine expression to
the expression of HPRT1. * no positive signal with 45 cycles.
doi:10.1371/journal.pone.0126564.g009
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Renal injury in LN is initiated by deposition of autoantibodies and/or ICs in glomeruli, lead-
ing to activation of complement and macrophages, cell proliferation, production of extracellu-
lar matrix proteins, and pro-inflammatory cytokines and chemokines, which are linked
through multiple mechanisms resulting in tubule damage, tubulointerstitial inflammation and
fibrosis [4, 5]. Depending on the type, duration and severity of LN, immune deposits can be
observed in the sub-epithelial, sub-endothelial, mesangial, and tubulointerstitial regions. Depo-
sition of cationic immune deposits in the sub-endothelial or mesangial regions can initiate the
recruitment of inflammatory cells and activation of resident endothelial and mesangial cells.
Immune deposits in the sub-epithelial region are related to podocyte injury and proteinuria,
whereas the glomerular basement membrane (GBM) acts as a barrier to leukocyte infiltration.
The main property of autoantibodies that is required for induction of nephritis is an ability
to be deposited in the kidney and initiate inflammation. Anti-dsDNA antibodies are believed
to play a central role in the pathogenesis of LN [4–6]. However, the exact mechanism through
which anti-dsDNA antibodies are deposited in the kidney remains to be fully elucidated. Three
mechanisms have been proposed to explain the propensity of anti-dsDNA antibodies to local-
ize in the kidney. One is the formation of ICs with an ability to bind DNA/nucleosomes
released from apoptotic cells [8, 54–56]. These ICs can deposit in the kidney and initiate an
inflammatory cascade, interfering with the normal filtration barrier and causing proteinuria.
Evidence for this theory is derived from the presence of DNA-anti-dsDNA complexes in the
sera of LN patients, and elution of anti-dsDNA antibodies from diseased kidneys. The second
theory, the planted antigen theory, suggests that anti-dsDNA antibodies form in the kidney by
reacting with DNA/nucleosomes trapped in the GBM [57, 58]. The trapping of DNA/nucleo-
somes in the GBM has been attributed to charge interactions between DNA and the GBM. The
third putative mechanism involves cross-reactivity between anti-dsDNA antibodies and kidney
antigens including α-actinin, α-enolase, annexin II, annexin AI, and ribosomal P protein [21–
28]. Although there is a general correlation between the presence of anti-dsDNA antibodies
and SLE, several studies have demonstrated a discrepancy with LN. Alba et al. investigated dif-
ferent populations of autoantibodies in SLE patients with LN, as confirmed by renal biopsy
[59]. Almost 99% of SLE patients with or without nephritis were positive for anti-nuclear anti-
bodies. On the other hand, anti-dsDNA antibodies were positive in only 68% of patients with
LN and about half of SLE patients without LN. This suggests that other autoantibodies contrib-
ute to the pathogenesis of LN.
Autoantibodies other than anti-dsDNA antibodies have been reported in LN patients [9–
27]. Anti-C1q antibody is associated with LN [9–15]. C1q plays a crucial role in the clearance
of apoptotic cells and immune complexes [60]. Both humans and mice with C1q deficiency
have a risk of developing lupus-like syndromes and immune-mediated glomerulonephritis
because of defective clearance of apoptotic cells, autoantigens, and immune complexes [61].
The prevalence of anti-C1q antibody in LN patients is 40–97%, and elevation of the anti-C1q
titer predicts the development of LN or renal flares [15]. However, anti-C1q antibody has been
reported in 45% of SLE patients without nephritis [13]. In addition, the presence of anti-C1q
antibody has been demonstrated in patients with hypocomplementemic urticarial vasculitis,
rheumatoid arthritis, non-SLE active glomerulonephritis, and human immunodeficiency virus
infection [14]. Anti-nucleosome antibodies are also associated with LN, and their prevalence in
LN patients is 60–90% [15–19]. Nucleosomes released by apoptotic cells are major T and B cell
autoantigens in SLE [62]. A recent electron microscopy study of renal tissues from LN patients
demonstrated that autoantibodies were colocalized with electron-dense extracellular deposits
of chromatin, suggesting that intraglomerular membrane-associated nucleosomes are targeted
by nephritogenic autoantibodies [63]. The frequency of anti-nucleosome antibodies in active
SLE is similar to that of anti-dsDNA antibodies, and the titers of these autoantibodies have
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correlated with each other in most studies [16–19]. However, the performance of anti-nucleo-
some antibodies for predicting LN or renal flares does not appear to be superior to that of anti-
dsDNA antibodies. Anti-Sm antibodies react with the common heptamer of U1, U2, U4, and
U5 small-nuclear RNP, and anti-Sm antibodies are associated with the severity and activity of
renal disease [8, 20]. Anti-dsDNA antibodies are also well known to cross-react with compo-
nents of the cytoplasm and plasma membrane of the GBM, such as α-actinin, α-enolase,
annexin II, annexin AI, and ribosomal P protein [21–27]. However, these autoantibodies do
not have sufficient sensitivity and specificity for predicting LN or renal flares.
To obtain further clinical markers for diagnosis of LN and evaluation of its activity, we
screened autoantigens reactive with serum antibodies from LN patients using a BPL-based
screening method, which is useful for identification of autoantigen proteins reactive with auto-
antibodies recognizing conformational epitopes [29, 30]. After analysis using several methods,
we identified two autoantigens, RRP8 and TNP1, that were associated with LN. Circulating
anti-RRP8 and anti-TNP1 autoantibodies were recognized and deposited as ICs in the glomer-
uli of some LN patients. In addition, the positivity rates for both anti-RRP8 and anti-TNP1
autoantibodies were significantly higher in the LN group than in the SLE group without
nephritis. From these findings, we concluded that RRP8 and TNP1 autoantigens were associ-
ated with LN. RRP8 is a cationic protein (pI = 9.87) consisting of 456 amino acids (a.a.) (molec-
ular mass 50.7 kDa), localized mainly in the nucleolus [31]. The a.a. sequence of human RRP8
shows 76% homology with that of mouse RRP8, and expression of RRP8 was detected in all 16
tissues (S10 Fig). RRP8 is an essential component of the eNoSC complex and acts by recruiting
histone-modifying enzymes [33–35]. The eNoSC complex is able to sense the energy status of
cells: upon glucose starvation, elevation of the NAD (+)/NADP (+) ratio activates sirtuin 1,
leading to histone H3 deacetylation followed by dimethylation of H3 at lysine 9 (H3K9me2)
and the formation of silent chromatin in the rDNA locus. In the complex, RRP8 binds to
H3K9me2 and acts as a methyltransferase. On the other hand, TNP1, also a cationic protein
(pI = 12.33), consists of 55 a.a. (molecular mass 6.4 kDa) [32]. The a.a. sequence of human
TNP1 shows 87% homology with its mouse counterpart. TNP1 is a basic protein expressed in
the sperm nucleus and participates in chromatin condensation by replacing somatic-type his-
tones with protamines during spermiogenesis [36]. TNP1 was highly expressed in testis, but
moderately expressed in pancreas, thymus and prostate, and only weakly expressed in liver and
ovary (S10 Fig) [64]. The GBM normally functions as both a size and a charge barrier to filtra-
tion of macromolecules. Especially, anionic sites located throughout all the layers of the GBM
play a crucial role in the transglomerular passage of macromolecules, since it facilitates the pas-
sage of cationic macromolecules to a greater extent than that of anionic and neutral macromol-
ecules [65, 66]. Both RRP8 and TNP1 are cationic proteins. Sera of mice immunized with
recombinant RRP8 and TNP1 did not cross-react with dsDNA. These findings suggest that
these proteins, when released from apoptotic cells, form ICs with each autoantibody and that
these ICs may be trapped at anionic sites in the GBM, leading to deposition in glomeruli.
Both anti-RRP8 and anti-TNP1 autoantibodies were detected in the sera of MRL/lpr mice
that developed nephritis, closely resembling the pattern seen in human LN. Therefore, we
planned to investigate whether glomerulonephritis would be induced by injecting recombinant
mouse RRP8 or mouse TNP1 protein into mice. However, we were unable to initiate this exper-
iment because no antibodies against mouse RRP8 or mouse TNP1 suitable for histological anal-
ysis were available commercially. Therefore, we examined whether IC would be formed by
injection of human RRP8 or TNP1 into C57BL/6 mice and whether glomerulonephritis would
occur predominantly as a result of IC formation with RRP8 or TNP1. IC-deposited glomerulo-
nephritis was induced in C56BL/6 mice by repeated stimulation with recombinant human
RRP8 or TNP1 protein. Furthermore, IC formed with RRP8 or TNP1 was deposited
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preferentially in glomeruli rather than in other organs. In the kidneys of RRP8-injected and
TNP1-injected mice, cells showing predominant infiltration were macrophages in glomeruli
and T cells in the tubulointerstitium. The affected kidneys showed a predominant Th1 immune
response, as the expression level of IFN-γ was high relative to that of IL-4 or IL-17A. Previous
studies of infiltrating cells and immune balance in the kidneys of LN patients have indicated
that in the glomeruli of patients with diffuse proliferative lupus nephritis (DPLN), the majority
of infiltrating cells were macrophages, while T cells were somewhat rarer. In contrast, the major
infiltrating cells in the interstitium were both T cells and macrophages, with a predominance of
T cells, and a Th1 immune response was predominant in the renal tissues [67]. These findings
resemble the features of glomerulonephritis seen in RRP8-injected and TNP1-injected mice.
In the present study, we identified two novel LN-associated autoantigens, RRP8 and TNP1.
The levels of anti-RRP8 and anti-TNP1 autoantibodies did not correlate with those of anti-
dsDNA antibodies in some LN patients. In addition, sera of mice immunized with recombinant
RRP8 and TNP1 did not cross-react with dsDNA. Therefore, these autoantibodies may be use-
ful for diagnosis and prediction of LN in subsets of SLE patients who are negative for anti-
dsDNA antibodies. Because of the small number of LN patients investigated in this study, no
definite conclusion can be drawn about the association between the levels of these autoantibod-
ies and LN disease activity. Further investigations will be necessary to determine whether anti-
RRP8 and anti-TNP1 antibodies can be used as biomarkers of LN disease activity, and for eval-
uating the performance of panels of LN-associated autoantibodies for diagnosis, monitoring,
and prognostic stratification of patients with LN.
Supporting Information
S1 Fig. Nonspecific fluorescence of formalin-fixed, paraffin-embedded sections of kidneys.
Formalin-fixed, paraffin-embedded sections of kidneys were stained with secondary antibody
only; Alexa Fluor 546-conjugated anti-rabbit IgG antibody (A) or FITC-conjugated anti-rabbit
IgG antibody (B). Panel (C) is merged image. The strong autofluorescence in each panel is
mainly due to red blood cells.
(TIF)
S2 Fig. Measurement of anti-RRP8 (A) and anti-TNP1 (B) antibodies in the serum samples
of MRL/lpr mice. The serum samples were prepared fromMRL/lpr mice at ages 8, 12, and 20
weeks during the development of nephritis. Serum samples were assayed by ELISA using puri-
fied mouse RRP8 or TNP1 protein. The sera of C57BL/6 mice were used as a control.
(TIF)
S3 Fig. Immunofluorescence (positive control) of RRP8 or TNP1 and IgG in the kidneys of
RRP8-injected or TNP1-injected mice.
(TIF)
S4 Fig. Immunofluorescence of RRP8 and IgG in the lungs of RRP8-injected mice.Normal
C57BL/6 mice were used as a control. Representative photographs are shown.
(TIF)
S5 Fig. Immunofluorescence of TNP1 and IgG in the lungs of TNP1-injected mice.
(TIF)
S6 Fig. Immunofluorescence of RRP8 and IgG in the spleen of RRP8-injected mice.
(TIF)
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S7 Fig. Immunofluorescence of TNP1 and IgG in the spleen of TNP1-injected mice.
(TIF)
S8 Fig. Immunofluorescence of RRP8 and IgG in the liver of RRP8-injected mice.
(TIF)
S9 Fig. Immunofluorescence of TNP1 and IgG in the liver of TNP1-injected mice.
(TIF)
S10 Fig. Expressions of TNP1 and RRP8 in the human tissues. The expressions of TNP1 and
RRP8 were analyzed with PCR using MTC cDNA panels.
(TIF)
S1 Table. Clinical and laboratory data of 11 LN patients.
(PDF)
S2 Table. Clinical and laboratory data of patient A and B.
(PDF)
S3 Table. Clinical and laboratory data of 20 patients analyzed with immunoprecipitation.
(PDF)
S4 Table. Information on 238 patients and 41 healthy individuals analyzed with ELISA.
(PDF)
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